Calamos Advisors LLC Makes New $515,000 Investment in LENZ Therapeutics, Inc. $LENZ

Calamos Advisors LLC acquired a new stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 17,565 shares of the company’s stock, valued at approximately $515,000. Calamos Advisors LLC owned about 0.06% of LENZ Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Banque Transatlantique SA bought a new stake in LENZ Therapeutics during the 1st quarter valued at $119,000. Police & Firemen s Retirement System of New Jersey increased its position in shares of LENZ Therapeutics by 63.6% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 4,130 shares of the company’s stock valued at $121,000 after acquiring an additional 1,605 shares during the period. AlphaQuest LLC bought a new position in shares of LENZ Therapeutics during the first quarter valued at about $168,000. Westfield Capital Management Co. LP purchased a new stake in shares of LENZ Therapeutics during the first quarter worth about $261,000. Finally, Swiss National Bank grew its stake in shares of LENZ Therapeutics by 12.7% in the first quarter. Swiss National Bank now owns 21,300 shares of the company’s stock worth $548,000 after purchasing an additional 2,400 shares during the last quarter. Institutional investors own 54.32% of the company’s stock.

Insider Activity at LENZ Therapeutics

In related news, CFO Daniel R. Chevallard acquired 2,198 shares of LENZ Therapeutics stock in a transaction that occurred on Friday, November 7th. The stock was bought at an average price of $22.76 per share, with a total value of $50,026.48. Following the transaction, the chief financial officer directly owned 5,386 shares in the company, valued at approximately $122,585.36. This represents a 68.95% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director James W. Mccollum bought 10,500 shares of the company’s stock in a transaction on Friday, November 7th. The stock was bought at an average cost of $22.79 per share, for a total transaction of $239,295.00. Following the completion of the acquisition, the director directly owned 10,500 shares of the company’s stock, valued at approximately $239,295. This represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. 6.90% of the stock is currently owned by company insiders.

LENZ Therapeutics Trading Down 3.4%

Shares of LENZ Therapeutics stock opened at $25.60 on Friday. LENZ Therapeutics, Inc. has a 12 month low of $16.53 and a 12 month high of $50.40. The firm has a market capitalization of $801.02 million, a P/E ratio of -12.13 and a beta of 0.46. The business has a fifty day simple moving average of $36.95 and a two-hundred day simple moving average of $33.77.

LENZ Therapeutics (NASDAQ:LENZ) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.08. The business had revenue of $12.50 million during the quarter, compared to the consensus estimate of $4.64 million. Analysts predict that LENZ Therapeutics, Inc. will post -2.18 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on LENZ. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of LENZ Therapeutics in a research report on Wednesday, October 8th. HC Wainwright restated a “buy” rating and set a $56.00 target price on shares of LENZ Therapeutics in a report on Monday, October 27th. Raymond James Financial reiterated an “outperform” rating and issued a $50.00 price target (up previously from $40.00) on shares of LENZ Therapeutics in a report on Monday, October 20th. Zacks Research upgraded shares of LENZ Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 22nd. Finally, Piper Sandler raised their target price on shares of LENZ Therapeutics to $67.00 and gave the stock an “overweight” rating in a research report on Friday, October 10th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, LENZ Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $56.40.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.